The company will offer 4 million shares of common stock at a price of $12.50 per share, with an option for underwriters to purchase up to an additional 600,000 shares.
NanoString Technologies hopes to use proceeds from the stock offering to support the commercial launch of its Digital Spatial Profiling platform next year.
The firm said it will offer 4.5 million shares of its common stock at $20 per share. It expects to close its follow-on public offering on July 16.
Net proceeds from the exercise of subscription rights and warrants are anticipated to be $22.6 million, excluding any proceeds from the exercise of warrants.
The molecular diagnostics company previously raised $180 million in its 2015 initial public offering.
The company said it will use the proceeds for the US commercial launch of its Unyvero molecular diagnostic platform, among other things.
The company recently disclosed that the commercial launch of its liquid biopsy lung cancer diagnostic had been delayed.
The firm increased the number of shares it was offering after its stock price fell sharply this week.
JP Morgan Securities and Cowen and Company are the joint book-running managers for the offering, while William Blair is the lead manager.
The company had intended to raise up to €6.6 million through the placement to help fund its planned acquisition of TGR Biosciences.
In PLOS this week: Mycobacterium abscessus linked to gastric conditions, placental gene expression changes associated with preterm birth, and more.
The Guardian reports that UK universities are looking into ways to reduce labs' reliance on single-use plastics.
People with certain gene variants tend to not like vegetables, particularly bitter ones, CNN reports.
MIT's Technology Review reports on a company's genetic test that gauges an embryo's susceptibility to certain diseases.